Vir Biotechnology Inc. (VIR)
Vir Biotechnology Inc. (VIR) Stock Price, Analysis & Data
| Bid | 6.47 |
| Market Cap | 1.52B |
| Revenue (ttm) | 303.23M |
| Net Income (ttm) | -251.68M |
| Beta | 1.59 |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.59 |
| P/B (ttm) | 1.78 |
| P/S (ttm) | 5.00 |
| Earnings Date | Nov 4, 2026 |
| Ask | 11.44 |
| Volume | 896,152 |
| Avg. Volume (20D) | 1,853,704 |
| Open | 8.89 |
| Previous Close | 8.93 |
| Day's Range | 8.86 - 9.09 |
| 52-Week Range | 4.25 - 11.66 |
| Analyst | Strong Buy |
| Price Target | 20 (123.21%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody d...
Financial Performance
In 2025, Vir Biotechnology's revenue was 66.52M, an increase of 4.41% compared to the previous year's 63.71M. Earnings were -437.99M, a decrease of -16.09%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for VIR stock is "Strong Buy". The 12-month stock price forecast is 20, which is upside of 123.21% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
